Actively recruiting phase 2 trial of PVSRIPO and pembrolizumab for recurrent glioblastoma
Learn more about the LUMINOS-101 study design in recurrent GBM
See the LUMINOS-101 rGBM protocol featured at ASCO 2021
Review phase 1 results published in the NEJM
Visit the LUMINOS-101
study protocol page on clinicaltrials.gov
Learn more about the LUMINOS-101 study design in recurrent GBM
See the LUMINOS-101 rGBM protocol featured at ASCO 2021
Review phase 1 results published in the NEJM
Visit the LUMINOS-101 study protocol page on clinicaltrials.gov
The LUMINOS-101 trial is designed to build on the results of the phase 1 trial of PVSRIPO in recurrent glioblastoma, in which unprecedented 5-year survival was observed.
See an overview of LUMINOS-101
Featured presentation at ASCO 2021: design of the LUMINOS-101 study of PVSRIPO in recurrent GBM
Andrew E. Sloan, MD, MBA, FACS, of the University Hospitals-Cleveland Medical Center and Seidman Cancer Center reviews the rationale for investigation of PVSRIPO in recurrent GBM and the design of the ongoing LUMINOS-101 phase 2 study of PVSRIPO with pembrolizumab in this disease.
Featured presentation at ASCO 2021: design of the LUMINOS-101 study of PVSRIPO in recurrent GBM
Andrew E. Sloan, MD, MBA, FACS, of the University Hospitals-Cleveland Medical Center and Seidman Cancer Center reviews the rationale for investigation of PVSRIPO in recurrent GBM and the design of the ongoing LUMINOS-101 phase 2 study of PVSRIPO with pembrolizumab in this disease.
Review the phase 1 results
Access the peer-reviewed publication in the New England Journal of Medicine with the results of the phase 1 trial of PVSRIPO in recurrent glioblastoma